neuromind biopharma ltd
neuromind biopharma ltd Company Information
Company Number
13342081
Next Accounts
45 days late
Shareholders
roger jones
andreis meyer
View AllGroup Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
wey court west union road, farnham, surrey, GU9 7PT
Website
neuromindbiopharma.comneuromind biopharma ltd Estimated Valuation
Pomanda estimates the enterprise value of NEUROMIND BIOPHARMA LTD at £0 based on a Turnover of £0 and 1.26x industry multiple (adjusted for size and gross margin).
neuromind biopharma ltd Estimated Valuation
Pomanda estimates the enterprise value of NEUROMIND BIOPHARMA LTD at £0 based on an EBITDA of £-46.5k and a 5.31x industry multiple (adjusted for size and gross margin).
neuromind biopharma ltd Estimated Valuation
Pomanda estimates the enterprise value of NEUROMIND BIOPHARMA LTD at £53.6k based on Net Assets of £30.1k and 1.78x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Neuromind Biopharma Ltd Overview
Neuromind Biopharma Ltd is a live company located in surrey, GU9 7PT with a Companies House number of 13342081. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in April 2021, it's largest shareholder is roger jones with a 24.8% stake. Neuromind Biopharma Ltd is a startup, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Neuromind Biopharma Ltd Health Check
Pomanda's financial health check has awarded Neuromind Biopharma Ltd a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 0 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
0 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Neuromind Biopharma Ltd
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Neuromind Biopharma Ltd
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Neuromind Biopharma Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 337 weeks, this is more cash available to meet short term requirements (10 weeks)
- - Neuromind Biopharma Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 15.3%, this is a lower level of debt than the average (46.2%)
- - Neuromind Biopharma Ltd
- - Industry AVG
NEUROMIND BIOPHARMA LTD financials
Neuromind Biopharma Ltd's latest turnover from April 2023 is estimated at 0 and the company has net assets of £30.1 thousand. According to their latest financial statements, we estimate that Neuromind Biopharma Ltd has no employees and maintains cash reserves of £35.4 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Apr 2023 | Apr 2022 | |
|---|---|---|
| Turnover | ||
| Other Income Or Grants | ||
| Cost Of Sales | ||
| Gross Profit | ||
| Admin Expenses | ||
| Operating Profit | ||
| Interest Payable | ||
| Interest Receivable | ||
| Pre-Tax Profit | ||
| Tax | ||
| Profit After Tax | ||
| Dividends Paid | ||
| Retained Profit | ||
| Employee Costs | ||
| Number Of Employees | ||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Apr 2023 | Apr 2022 | |
|---|---|---|
| Tangible Assets | ||
| Intangible Assets | ||
| Investments & Other | ||
| Debtors (Due After 1 year) | ||
| Total Fixed Assets | ||
| Stock & work in progress | ||
| Trade Debtors | ||
| Group Debtors | ||
| Misc Debtors | 190 | 250 |
| Cash | 35,368 | |
| misc current assets | ||
| total current assets | 35,558 | 250 |
| total assets | 35,558 | 250 |
| Bank overdraft | ||
| Bank loan | ||
| Trade Creditors | ||
| Group/Directors Accounts | ||
| other short term finances | ||
| hp & lease commitments | ||
| other current liabilities | 5,454 | |
| total current liabilities | 5,454 | |
| loans | ||
| hp & lease commitments | ||
| Accruals and Deferred Income | ||
| other liabilities | ||
| provisions | ||
| total long term liabilities | ||
| total liabilities | 5,454 | |
| net assets | 30,104 | 250 |
| total shareholders funds | 30,104 | 250 |
| Apr 2023 | Apr 2022 | |
|---|---|---|
| Operating Activities | ||
| Operating Profit | ||
| Depreciation | ||
| Amortisation | ||
| Tax | ||
| Stock | ||
| Debtors | -60 | 250 |
| Creditors | ||
| Accruals and Deferred Income | 5,454 | |
| Deferred Taxes & Provisions | ||
| Cash flow from operations | ||
| Investing Activities | ||
| capital expenditure | ||
| Change in Investments | ||
| cash flow from investments | ||
| Financing Activities | ||
| Bank loans | ||
| Group/Directors Accounts | ||
| Other Short Term Loans | ||
| Long term loans | ||
| Hire Purchase and Lease Commitments | ||
| other long term liabilities | ||
| share issue | ||
| interest | ||
| cash flow from financing | ||
| cash and cash equivalents | ||
| cash | 35,368 | |
| overdraft | ||
| change in cash | 35,368 |
neuromind biopharma ltd Credit Report and Business Information
Neuromind Biopharma Ltd Competitor Analysis
Perform a competitor analysis for neuromind biopharma ltd by selecting its closest rivals, whether from the MANUFACTURING sector, other startup companies, companies in GU9 area or any other competitors across 12 key performance metrics.
neuromind biopharma ltd Ownership
NEUROMIND BIOPHARMA LTD group structure
Neuromind Biopharma Ltd has no subsidiary companies.
Ultimate parent company
NEUROMIND BIOPHARMA LTD
13342081
neuromind biopharma ltd directors
Neuromind Biopharma Ltd currently has 3 directors. The longest serving directors include Sir Roger Jones (Oct 2021) and Andreis Meyer (Oct 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Sir Roger Jones | United Kingdom | 81 years | Oct 2021 | - | Director |
| Andreis Meyer | United Kingdom | 49 years | Oct 2021 | - | Director |
| Mr Pierre Coertzen | United Kingdom | 49 years | Feb 2024 | - | Director |
P&L
April 2023turnover
0
0%
operating profit
-46.5k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
April 2023net assets
30.1k
+119.42%
total assets
35.6k
+141.23%
cash
35.4k
0%
net assets
Total assets minus all liabilities
Similar Companies
neuromind biopharma ltd company details
company number
13342081
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
April 2021
age
4
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
April 2023
previous names
N/A
accountant
-
auditor
-
address
wey court west union road, farnham, surrey, GU9 7PT
Bank
-
Legal Advisor
-
neuromind biopharma ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to neuromind biopharma ltd.
neuromind biopharma ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEUROMIND BIOPHARMA LTD. This can take several minutes, an email will notify you when this has completed.
neuromind biopharma ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
